An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)

Sponsor
Hoffmann-La Roche
Study ID
NCT01075477
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This observational study will assess the execution, efficacy and safety of treatment with MabThera in patients with rheumatoid arthritis. Data from patients receiving MabThera according to local treatment guidelines will be collected for 29 months. Target sample size is 100-200 patients.

Key Dates

Start date
Sep 30, 2009
Status verified
Nov 2016
Primary completion
Dec 31, 2011
Completion
Dec 31, 2011

Study Design

Enrollment
151 participants (actual)

Arms

  • Arm: Cohort

Primary Outcome Measure

Efficacy: DAS28 [ Time Frame: 29 months ]

Related Studies